Literature DB >> 10863812

The female condom.

K McNamee.   

Abstract

BACKGROUND: The female condom has been available in numerous countries for some years. It was launched in Australia on March 8th, 2000 and is an important addition to the range of barrier contraceptives.
OBJECTIVE: This article aims to provide an overview of the female condom to enable GPs and nurse practitioners to advise clients and provide information about its use. DISCUSSION: The female condom is an effective form of contraception. When used correctly it has a failure rate of about 5%, which compares favourably with other forms of barrier contraception. It is important that users are instructed on insertion, in particular the need to guide the penis into the condom. Evidence shows that it reduces the incidence of sexually transmitted infections. There may also be additional benefit in reducing wart virus and herpes transmission, as there is greater protection to the vulva and the base of the penis, when compared with the male condom. The female condom has high user acceptability, and offers advantages in terms of sensitivity and also ease of use by men with erectile dysfunction. It is the only barrier protection under a woman's control, giving protection to the vagina and vulva as well as the cervix.

Entities:  

Mesh:

Year:  2000        PMID: 10863812

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  2 in total

1.  Female Condom Use and Its Acceptability Among HIV-serodiscordant Couples in China.

Authors:  Lahong Ju; Cynthia X Shi; Fan Lv; Houlin Tang; Gang Zeng; Peng Xu; Wanying Chen; Huijing He; Liping Ma; Linglin Zhang; Xi Chen
Journal:  J Assoc Nurses AIDS Care       Date:  2019 Jul-Aug       Impact factor: 1.354

2.  Views and experiences of the female condom in Australia: An exploratory cross-sectional survey of cisgender women.

Authors:  Sarah E Fenwick; Jessica R Botfield; Prudence Kidman; Kevin McGeechan; Deborah Bateson
Journal:  PLoS One       Date:  2021-02-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.